openPR Logo
Press release

Lawsuit filed for Investors in shares of Molecular Partners AG (NASDAQ: MOLN)

08-09-2022 12:15 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Molecular Partners AG (NASDAQ: MOLN) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Molecular Partners AG (NASDAQ: MOLN) shares over alleged securities laws violations.

An investor, who purchased shares of Molecular Partners AG (NASDAQ: MOLN), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Molecular Partners AG (NASDAQ: MOLN in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Molecular Partners AG (NASDAQ: MOLN) have certain options and for certain investors are short and strict deadlines running. Deadline: September 12, 2022. NASDAQ: MOLN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Switzerland based Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Leading up to and following the IPO, Molecular Partners AG repeatedly touted the clinical and commercial prospects of certain of its product candidates under development in collaboration with other companies.
Among other product candidates, Molecular Partners AG is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG ("Novartis"). One of the Company's most important development strategies for ensovibep includes securing Emergency Use Authorization ("EUA") for ensovibep from the U.S. Food and Drug Administration ("FDA").
In addition, Molecular Partners AG is developing MP0310 (AMG 506) for the treatment of certain types of cancer in collaboration with Amgen Inc. ("Amgen"). The Company granted Amgen, among other licenses, the right to progress MP0310's development program into later stage development, including into combination trials, following Phase 1 data.
On April 22, 2021, Molecular Partners AG filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") in connection with the IPO, which, after several amendments, was declared effective by the SEC on June 15, 2021 (the "Registration Statement").
On June 16, 2021, Molecular Partners filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (collectively, the "Offering Documents").
Pursuant to the Offering Documents, Molecular Partners AG conducted the IPO, issuing 3 million of its ADSs to the public at the IPO price $21.25 per ADS, for proceeds to the Company of over $59 million, after underwriting discounts and commissions, and before expenses.

On November 16, 2021, Molecular Partners AG disclosed that "a planned futility analysis of ensovibep in [an] ongoing [Phase 3] clinical study . . . has not met the thresholds required to continue enrollment of adults with COVID-19 in the hospitalized setting."

On April 26, 2022, months after applying for EUA from the FDA for ensovibep, Novartis' Chief Executive Officer, Vas Narasimhan, disclosed that "given the latest feedback . . . in our discussions with the [FDA], we would expect the agency to require a Phase 3 study before granting an EUA approval or a general approval" for ensovibep, and that "we need to make a kind of sober evaluation as to is it a doable study in light of the waning rates of COVID around the world[.]"

Then, also on April 26, 2022, during after-market hours, Molecular Partners AG "announced that Amgen . . . has informed the Company of their decision to return global rights of MP0310 to Molecular Partners following a strategic pipeline review."

Shares of Molecular Partners AG (NASDAQ: MOLN) declined to as loaw as $5.92 per share on May 12, 2022.

The plaintiff claims that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, The plaintiff alleges that between June 16, 2021 and April 26, 2022 the Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

More specifically, the plaintiff claims that the the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) ensovibep was less effective at treating COVID-19 than Defendants had led investors to believe; (ii) accordingly, the FDA was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug EUA; (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) as a product candidate, MP0310 was less attractive to Amgen than Defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, the Offering Documents and Defendants' public statements between June 16, 2021 and April 26, 2022 were materially false and/or misleading and failed to state information required to be stated therein.

Those who purchased shares of Molecular Partners AG (NASDAQ: MOLN) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Molecular Partners AG (NASDAQ: MOLN) here

News-ID: 2700809 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Molecular

Molecular Breeding Market Report 2024 - Molecular Breeding Market Size, Share An …
"The Business Research Company recently released a comprehensive report on the Global Molecular Breeding Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The molecular breeding market size
Molecular Quality Controls: Ensuring Precision and Reliability in Molecular Diag …
Introduction Molecular quality controls (MQCs) play a critical role in molecular diagnostics, helping laboratories and healthcare providers ensure the accuracy, reliability, and consistency of diagnostic tests. These quality controls are essential in detecting and monitoring infectious diseases, genetic disorders, cancer biomarkers, and other molecular targets. By providing standards that verify the performance of diagnostic assays, MQCs help reduce errors, minimize false results, and maintain compliance with regulatory standards. As the demand
Molecular Diagnostic Platform Market Advancing Molecular Diagnostics with Innova …
Global Molecular Diagnostic Platform Market Overview: The Molecular Diagnostic Platform market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others. In recent years, the Molecular Diagnostic Platform market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth
Molecular Modeling Market - Visualizing the unseen: Molecular modeling for grou …
Newark, New Castle, USA: The "Molecular Modeling Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Molecular Modeling Market: https://www.growthplusreports.com/report/molecular-modeling-market/8615 This latest report researches the industry structure, sales, revenue,
Molecular Diagnostics Market - Empowering healthcare through molecular precision …
Newark, New Castle, USA: The "Molecular Diagnostics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Molecular Diagnostics Market: https://www.growthplusreports.com/report/molecular-diagnostics-market/7674 This latest report researches the industry structure, sales, revenue,
Molecular Imaging Device Market scenario for 2022 | Trivitron Healthcare, Molecu …
The Molecular Imaging Device market report anticipate the market growth and recent developments in market competition which helps players to strategies and analysis the position in Molecular Imaging Device market. It also indicates the risk factors, advancements, market drivers, revenue, business scenario, growth potential, market scope, new trends, and historical data of Molecular Imaging Device market. With this futuristic approach researchers also provides a close study of market forecast, overview